The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHemogenyx Media (HEMO)

Share Price Information for Hemogenyx (HEMO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.475
Bid: 1.45
Ask: 1.50
Change: 0.00 (0.00%)
Spread: 0.05 (3.448%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1.475
HEMO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

RNS EXCLUSIVE: HemoGenyx release successful CDX Antibody first data results

Dr Vladislav Sandler, Co-Founder and CEO of HemoGenyx Pharmaceuticals #LSE #HEMO discusses two major announcements with London South East.

  1. First data results show that CDX antibodies have been successfully tested on real AML Leukemia cells. Dr Sandlar said he was 'ecstatic' when the results came through. These tests are specific to the blood cancer Acute Myelogenous Leukemia (AML) in vitro.
  2. HemoGenyx have been working with a new type of 'humanised mice' in these trials and have made a Patent application. These mice allow researchers to test and develop drugs in a much more efficient and fast way, in a live animal on a 'human background' using human cells which live inside that animal.

Dr Sandler hopes other organisations might use them for product development, other disease modelling and drug development and is in discussions with several organisations.

Related Hemogenyx Media

What's Hot 19th September 2023

What's Hot at Easter

EXCLUSIVE: HemoGenyx are creating blood cancer treatments with US$9 billion market potential

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.